The allocation and use of Developmental Funds has been managed centrally. Developmental Funds at UPCI have been utilized in two w/ays: 1) New Investigator and Program Support, to enhance research areas that have been identified in the strategic planning process as high priority for development and expansion; and 2) Pilot funding of UPCI member projects deemed by an internal advisory committee to be the most meritorious scientifically and likely to facilitate interactions among program members or to lead to subsequent success in obtaining major external funding. These developmental funds have been extremely helpful to vigorously promote the high priority goals of UPCI. The review of this funding category at the last competitive renewal ofthe CCSG rated it as having Excellent to Outstanding merit. Following the same approach that has been quite successful to date, it is proposed that the majority of funds being requested will be utilized to support recruitment in high priority areas for ongoing development and expansion. To a lesser extent, Developmental Funds will be used to fund pilot projects that explore innovative ideas and develop new collaborations as well as to enhance the capability of shared facilities to a lesser extent. We are requesting $278,079 towards faculty development, $200,000 for pilot projects and $100,000 for shared facilities development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-24
Application #
8382667
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$507,612
Indirect Cost
$78,574
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :

Showing the most recent 10 out of 1187 publications